Stefanie Kammerman, the Stock Whisperer, here to tell you the MoneyShow Dark Pool picks July 19: Gol...
Second Sight: The EYES Have it
08/18/2015 7:00 am EST
Of all the exciting new medical gadgets now on the market, one of the most impressive is the Argus II Retinal Prosthesis System, the world's first bionic eye, asserts Ernie Tremblay, editor of Money Morning.
The device is manufactured and sold by Second Sight Medical Products (EYES). It is approved by both the FDA and the European Union. It can restore some functional vision to people suffering from blindness.
Argus II has an HDE classification in the United States to provide electrical stimulation of the retina to induce visual perception.
Some types of blindness are caused by damage to cells in the back of the eye called photoreceptors, which come in two types: cones for perceiving visual color images in bright light, and rods, which are not receptive to color, for seeing in dimmer light and for peripheral vision.
Argus II bypasses these damaged cells via interplay between a miniature camera, a patient-worn visual processing unit (VPU), and an implant in the eye.
The camera, housed in the patient's glasses, passes an image to the VPU, which translates it into a set of instructions that are then transmitted—via the camera—to an antenna in the implant.
The implant, in turn, follows the instructions by sending certain electrical impulses to remaining healthy photoreceptors in the eye, which then pass along the message through the optic nerve to be decoded as an image in the brain.
About 1.5 million people around the world suffer from RP and about 2 million from WMD. Cost for one system is about $150,000, excluding surgery and the cost of learning how to use the system. The potential income for Second Sight is staggering.
EYES is also exploring use of the device in people with blindness due to a condition called wet macular degeneration.
And the company is living up to its promise. On August 4, 2015, the company reported it had grown net revenue by 335% to $2.7 million in the second quarter of 2015, compared to $0.6 million in the prior-year period.
With a market cap of $492 million and shares selling for around $13, this is an affordable stock poised to take off like a rocket. Buy Second Sight Medical Products at market and set a 35% trailing stop to protect your investment.
More from MoneyShow.com:
Related Articles on STOCKS
We are still on guard for corrective (even fairly volatile) declines in the weeks and months ahead, ...
From the Nov. 1, 2017 closing low at $5.07 to the March 26 closing high at $12.95, shares of Massach...
Big changes are coming this fall for investors and traders. The S&P 500 telecommunications servi...